D. Arenberg
University of Michigan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by D. Arenberg.
American Journal of Clinical Pathology | 2011
Bryan L. Betz; Michael H. Roh; Helmut C. Weigelin; Jeremiah Placido; Lindsay Schmidt; Sara Farmen; D. Arenberg; Gregory P. Kalemkerian; Stewart M. Knoepp
EGFR and KRAS mutation analyses are of increasing importance for guiding the treatment of non-small cell lung carcinomas. Insufficient cellularity of cell blocks can represent an impediment to the performance of these tests. We investigated the usefulness of cytologic direct smears as an alternative specimen source for mutation testing. Tumor cell-enriched areas from freshly prepared and archived rapid Romanowsky-stained direct smears in 33 cases of lung carcinoma were microdissected for DNA isolation and evaluated for EGFR and KRAS mutations. EGFR mutations were detected in 3 adenocarcinomas; 2 tumors had the L858R substitution and 1 an exon 19 deletion. KRAS mutations affecting codon 12, 13, or 61 were detected in 11 cases (8 adenocarcinomas and 3 non-small cell carcinomas). EGFR and KRAS mutations were mutually exclusive. Hence, archived and freshly prepared direct smears represent a robust and valuable specimen source for molecular studies, especially when cell blocks exhibit insufficient cellularity.
International Journal of Radiation Oncology Biology Physics | 2009
Li Wang; Candace R. Correa; James A. Hayman; L. Zhao; Kemp B. Cease; Dean E. Brenner; D. Arenberg; J. Curtis; Gregory P. Kalemkerian; Feng Ming Kong
PURPOSE To determine whether time to treatment (TTT) has an effect on overall survival (OS) in patients with unresectable or medically inoperable Stage III non-small cell lung cancer (NSCLC) and whether patient or treatment factors are associated with TTT. METHODS AND MATERIALS Included in the study were 237 consecutive patients with Stage III NSCLC treated at University of Michigan Hospital (UM) or the Veterans Affairs Ann Arbor Healthcare System (VA). Patients were treated with either palliative or definitive radiotherapy and radiotherapy alone (n = 106) or either sequential (n = 69) or concurrent chemoradiation (n = 62). The primary endpoint was OS. RESULTS Median follow-up was 69 months, and median TTT was 57 days. On univariate analysis, the risk of death did not increase significantly with longer TTT (p = 0.093). However, subset analysis showed that there was a higher risk of death with longer TTT in patients who survived >or= 5 years (p = 0.029). Younger age (p = 0.027), male sex (p = 0.013), lower Karnofsky Performance Score (KPS) (p = 0.002), and treatment at the VA (p = 0.001) were significantly associated with longer TTT. However, on multivariate analysis, only lower KPS remained significantly associated with longer TTT (p = 0.003). CONCLUSION Time to treatment is significantly associated with OS in patients with Stage III NSCLC who lived longer than 5 years, although it is not a significant factor in Stage III patients as a whole. Lower KPS is associated with longer TTT.
Journal of Thoracic Oncology | 2011
S. Yuan; Kirk A. Frey; Milton D. Gross; James A. Hayman; D. Arenberg; Jeffrey L. Curtis; Xu Wei Cai; Nithya Ramnath; Gregory P. Kalemkerian; Randall K. Ten Haken; Avraham Eisbruch; Feng Ming Kong
Introduction: Perfusion (Q) single photon emission computed tomography (SPECT) has been used to divert dose away from higher-functioning lung during radiation therapy (RT) planning. This study aimed to (1) study regional lung function through coregistered pulmonary ventilation/perfusion (V/Q)-SPECT-CT and (2) classify these defects for its potential value in radiation planning in patients with non-small cell lung cancer (NSCLC). Methods: Patients with stages I to III NSCLC requiring radiation-based therapy were eligible for this prospective study. V/Q-SPECT performed within 2 weeks before the start of radiation was interpreted by nuclear medicine physicians and then measured by a semiquantitative score. The potential mechanism of V and Q defects was analyzed; the potential impact of V/Q-SPECT over Q-SPECT alone was completed through classified applications (high-dose RT versus RT avoidance) during planning. Results: Images of 51 consecutive patients were analyzed. The V and Q defects were matched, reverse mismatched (V defect > Q defect), and mismatched (Q defect > V defect) in 61, 31, and 8% of patients, respectively. Tumor was the leading cause of the defects of ipsilateral lung in 73% of patients. The defect scores of the ipsilateral lung were greater in patients with central primaries than those with peripheral primaries for both V-SPECT (2.3 ± 1.1 versus 1.5 ± 0.8, p = 0.017) and Q-SPECT (2.2 ± 0.8 versus 1.4 ± 0.6, p = 0.000). The patients with chronic obstructive pulmonary disease had greater defect scores in contralateral lung for both V-SPECT (1.5 ± 0.7 versus 1.0 ± 0.8, p = 0.006) and Q-SPECT (1.4 ± 0.6 versus 1.0 ± 0.4, p = 0.010). On assessing the potential value of SPECT on RT plan, 39% of patients could have their RT plan when applying V/Q-SPECT rather than Q-SPECT alone. Conclusions: V/Q-SPECT provides a more comprehensive functional assessment, may provide additional value over Q-SPECT alone in assessing local pulmonary function, and guide RT plan decisions in patients with NSCLC.
Lung Cancer | 2008
L. Zhao; Kerby Sheldon; Ming Chen; Moli S. Yin; James A. Hayman; Gregory P. Kalemkerian; D. Arenberg; Susan E. Lyons; Jeffrey L. Curtis; Mary A. Davis; Kemp B. Cease; Dean E. Brenner; Mitchell S. Anscher; Theodore S. Lawrence; Feng Ming Kong
International Journal of Radiation Oncology Biology Physics | 2012
S. Yuan; Kirk A. Frey; Milton D. Gross; James A. Hayman; D. Arenberg; Xu Wei Cai; Nithya Ramnath; Khaled A. Hassan; Jean M. Moran; Avraham Eisbruch; Randall K. Ten Haken; Feng Ming Kong
International Journal of Radiation Oncology Biology Physics | 2012
W. Wang; Kerby Shedden; R.K. Ten Haken; J.A. Hayman; D. Arenberg; Theodore S. Lawrence; F. Kong
International Journal of Radiation Oncology Biology Physics | 2018
A.M. Laucis; Y. Sun; M. Schipper; C. Maurino; A. Saripalli; M. McFarlane; D. Arenberg; R.K. Ten Haken; F.M. Kong; M.M. Matuszak; D.E. Spratt; Lori J. Pierce; J.A. Hayman; P.A. Paximadis; Shruti Jolly
International Journal of Radiation Oncology Biology Physics | 2018
William C. Jackson; Philip S. Boonstra; Peter G. Hawkins; Dawn Owen; P. Jain; G. Sun; D. Arenberg; E. Lee; Gregory P. Kalemkerian; F.M. Kong; J.A. Hayman; Theodore S. Lawrence; R.K. Ten Haken; M. Schipper; M.M. Matuszak; Shruti Jolly
Journal of Thoracic Oncology | 2017
C. Anciano; Erik Folch; Sandeep J. Khandhar; D. Arenberg; O. Awais; D. Minnich; M. Pritchett; O. Rickman; E. Sztejman; Mark R. Bowling
International Journal of Radiation Oncology Biology Physics | 2017
W. Wang; M.M. Matuszak; H. Zhang; D. Arenberg; Jamie Curtis; Shruti Jolly; J. Jin; R.K. Ten Haken; F.M. Kong